Stocksigma LogoStocksigma Logo

Genpharmasec Approves Subsidiary Divestment and CS Resignation

Genpharmasec’s board approved the full divestment of its wholly owned subsidiary, Clinigenome India Private Limited, to Micro Genomics India Private

Genpharmasec Approves Subsidiary Divestment and CS Resignation

Genpharmasec Ltd · Change in Management · 03 Nov 2026, 11:08 pm

Genpharmasec Approves Subsidiary Divestment and CS Resignation Genpharmasec’s board approved the full divestment of its wholly owned subsidiary, Clinigenome India Private Limited, to Micro Genomics India Private Limited. Clinigenome contributed ₹100.47 Lakhs (0.72%) to consolidated turnover and had a net worth of ₹(154.41) Lakhs in the last financial year. The non-related-party transaction is slated for completion on or before 31st Mar'27, with financial consideration to be determined. Additionally, Company Secretary and Compliance Officer Hardik Makwana resigned, effective 16th Nov'26, to pursue external opportunities. Unaudited results for the period ended 30th Sep'26 were approved.

Original exchange filing (PDF)

More announcements from Genpharmasec Ltd

All Genpharmasec Ltd announcements